Amedeo Smart

Free Medical Literature Service

 

Amedeo

Prostate Cancer
  Free Subscription

Articles published in
Anticancer Res
    October 2025
  1. YUMISAKI H, Kubo N, Oike T, Kawamura H, et al
    A Dosimetric Evaluation of the Feasibility and Robustness of Ultra-hypofractionated Carbon Ion Radiotherapy Planning for the Treatment of Prostate Cancer.
    Anticancer Res. 2025;45:4453-4464.
    >> Share

  2. IMAFUKU H, Terashima K, Fukunishi K, Suefuji H, et al
    Carbon-Ion Radiotherapy for Prostate Cancer in Hemodialysis Patients.
    Anticancer Res. 2025;45:4465-4472.
    >> Share

  3. LEHRER S, Rheinstein PH
    PROX1 Expression Is Significantly Associated With ERG Expression and the TMPRSS2-ERG Fusion Gene in Prostate Cancer.
    Anticancer Res. 2025;45:4381-4388.
    >> Share

    September 2025
  4. NAKAI Y, Onishi K, Kagebayashi Y, Fujimoto K, et al
    Patients Diagnosed With Metastatic Castration-sensitive Prostate Cancer and High Serum Lactate Dehydrogenase Levels Did Not Receive an Adequate Dose of Cabazitaxel.
    Anticancer Res. 2025;45:3953-3960.
    >> Share

    August 2025
  5. HATTORI A, Seki T, Kato K, Virgona N, et al
    NK Cells Can Target Castration-resistant Prostate Cancer Stem Cells With the Involvement of Degranulation Pathway.
    Anticancer Res. 2025;45:3197-3207.
    >> Share

  6. BABU YSR, Venkatachalam KV
    Methionine Deprivation-induced Cancer Cell Death and Methylation Changes in Key Genes and Gene Promoters of Prostate Cancer Cell Lines.
    Anticancer Res. 2025;45:3209-3219.
    >> Share

    July 2025
  7. DEMIR U, Badoglu H, Cetin IN, Bener MY, et al
    A Novel Three Small Molecule Inhibitor Combination Therapy For Prostate Cancer.
    Anticancer Res. 2025;45:3077-3087.
    >> Share

  8. NGUYEN MD, Modestine JRD, Djoua Y, Gorobets O, et al
    Low-dose Apalutamide in Non-metastatic Castration-resistant Prostate Cancer: A Case Series.
    Anticancer Res. 2025;45:3127-3136.
    >> Share

    June 2025
  9. AIZAWA R, Ogata T, Goto T, Otani T, et al
    Clinical Outcomes of Metastasis-directed Therapy for Oligo-metastatic Prostate Cancer Diagnosed Using PSMA-PET/CT or Whole-body MRI.
    Anticancer Res. 2025;45:2515-2525.
    >> Share

  10. NGUYEN MD, Gorobets O, Djoua YJ, Rose-Dite-Modestine J, et al
    End-of-life Androgen Deprivation Syndrome With Enzalutamide in Metastatic Prostate Cancer: A Case Report.
    Anticancer Res. 2025;45:2535-2538.
    >> Share

    May 2025
  11. TAKASHIMA Y, Yoshii K, Tanaka M, Tashiro K, et al
    Ubiquitin-proteasome Pathway-linked Gene Signatures as Prognostic Indicators in Prostate Cancer.
    Anticancer Res. 2025;45:1825-1841.
    >> Share

  12. AOKI M, Matsui H, Kurihara S, Ohtake N, et al
    Comparison of BRCA2 Single Nucleotide Variants Between Japanese Patients With Familial Prostate Cancer, Sporadic Prostate Cancer, and Benign Prostatic Hyperplasia.
    Anticancer Res. 2025;45:2195-2204.
    >> Share

    April 2025
  13. NAKAI Y, Onishi K, Nakahama T, Kagebayashi Y, et al
    Evaluation of Candidates for Upfront Docetaxel Therapy Among Patients With Metastatic Castration-sensitive Prostate Cancer from a Retrospective Multicenter Study (MAHOROBA study).
    Anticancer Res. 2025;45:1653-1660.
    >> Share

    March 2025
  14. HIRATA J, Hara T, Jimbo N, Ueki H, et al
    Genomic Profiling of Small Cell Neuroendocrine Prostate Cancer and its Implications for Targeted Therapies.
    Anticancer Res. 2025;45:1137-1147.
    >> Share

  15. HSU JY, Ou HC, Ou YC, Lin YS, et al
    Safety and Outcomes of Intraoperative Ventriculoperitoneal Shunt Clamping During Robotic-assisted Radical Prostatectomy: Retrospective Cohort Analysis.
    Anticancer Res. 2025;45:1281-1289.
    >> Share

  16. NIEDER C, Haukland EC, Stanisavljevic L, Mannsaker B, et al
    Radiotherapy for Bone Metastases in Patients With Excellent Performance Status: Patterns of Care and Prognostic Factors for Survival.
    Anticancer Res. 2025;45:1149-1158.
    >> Share

  17. WU J, Lagunas AM, Crowe DL
    DNA Ligase 4 Inhibition Sensitizes Prostate Cancer to Immune Checkpoint Blockade In Vivo.
    Anticancer Res. 2025;45:883-896.
    >> Share

    February 2025
  18. RADES D, Kristiansen C, Vestergaard Madsen C, Kuter JD, et al
    Bladder Volume <200 ml During a Course of Moderate Hypofractionated Irradiation in Patients With Localized Prostate Cancer.
    Anticancer Res. 2025;45:701-708.
    >> Share

  19. HIROSHIGE T, Suekane H, Tokunaga T, Uegaki M, et al
    Prognostic Stratification Using Early Prostate-specific Antigen Kinetics in Men With Metastatic Hormone-sensitive Prostate Cancer.
    Anticancer Res. 2025;45:751-759.
    >> Share

    December 2024
  20. YIN W, He P, Zou Z, Lin J, et al
    SLC15A2 Serves as a Novel Prognostic Biomarker and Target for Prostate Cancer.
    Anticancer Res. 2024;45:153-172.
    >> Share

  21. KAMIMA T, Ueda Y, Fukunaga JI, Shimizu Y, et al
    Enhancing Estimation Accuracy of Prostate Cancer VMAT Planning: A Knowledge-based Approach Using Multiple Collimator Angles.
    Anticancer Res. 2024;44:5303-5312.
    >> Share

    October 2024
  22. RADES D, Cremers F, Ziemann C, Splettstosser L, et al
    Changes in Bladder Volume During Radiotherapy for Prostate Cancer.
    Anticancer Res. 2024;44:4457-4463.
    >> Share

  23. POULSEN TS, Lorup AN, Kongsted P, Eefsen RL, et al
    TMPRSS2:ERG Gene Fusion Might Predict Resistance to PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer.
    Anticancer Res. 2024;44:4203-4211.
    >> Share

    September 2024
  24. SATO M, Sato T, Hozumi C, Han Q, et al
    [(11)C]Methionine PET vs. [(18)F]Fluorodeoxyglucose PET Whole-body Imaging to Determine the Extent of Methionine-addiction Compared to Glucose-addiction of Primary and Metastatic Cancer of the Trunk in Patients.
    Anticancer Res. 2024;44:3891-3898.
    >> Share

    August 2024
  25. PICKETT C, Karunanandaa K, Stackable K, Eaton DB Jr, et al
    Prescription Medications and Overall Survival in Metastatic Hormone Sensitive Prostate Cancer.
    Anticancer Res. 2024;44:3443-3449.
    >> Share

    July 2024
  26. KUSTER JHS, Erb HHH, Ahrend H, Abazid A, et al
    Modulation of the Prostate Cancer Resistance Factor Hsp27 by the Chemotherapeutic Drugs Abiraterone, Cabazitaxel, Docetaxel and Enzalutamide.
    Anticancer Res. 2024;44:2815-2821.
    >> Share

  27. MITSUNARI K, Fukushima H, Kurata H, Harada J, et al
    Predictive Factors for Early Biochemical Recurrence Following Robot-assisted Radical Prostatectomy: The Impact of PSA Level, Gleason Score, and Pathological Tumor Stage.
    Anticancer Res. 2024;44:3149-3154.
    >> Share

  28. YAMAMOTO Y, Nishimoto M, Akashi Y, Kiba K, et al
    Impact of Novel Agents on Patient Characteristics, Treatment Patterns, and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer.
    Anticancer Res. 2024;44:3155-3161.
    >> Share

  29. HAN S, Jang S, Lee SW, Kim HY, et al
    hMAGEA2 Accelerates the Progression of Prostate Cancer via the EFNA3-Erk1/2 Signaling Pathway.
    Anticancer Res. 2024;44:2847-2859.
    >> Share

    June 2024
  30. WAKITA N, Hara T, Suzuki K, Terakawa T, et al
    Efficacy of Combination Therapy With Radium-223 and Enzalutamide in Castration-resistant Prostate Cancer With Bone Metastases.
    Anticancer Res. 2024;44:2627-2635.
    >> Share

  31. WAIBEL S, Graf N, Storz J, Schultze-Seemann S, et al
    Photoimmunotherapy of Prostate Cancer With Antibody and Fab Fragments Targeting the Prostate Specific Membrane Antigen.
    Anticancer Res. 2024;44:2343-2348.
    >> Share

  32. WANG YJ, Hao YY, Lee DH, Guo XY, et al
    Hispidin Increases Cell Apoptosis and Ferroptosis in Prostate Cancer Cells Through Phosphatidylinositol-3-Kinase and Mitogen-activated Protein Kinase Signaling Pathway.
    Anticancer Res. 2024;44:2533-2544.
    >> Share

    May 2024
  33. TAMBURO M, Buffettino E, Pepe P, Marletta G, et al
    Salvage Radiotherapy PSMA PET/CT-guided in Men With PSA Recurrence.
    Anticancer Res. 2024;44:2205-2210.
    >> Share

    April 2024
  34. MASUDA H, Amemiya Y, Yagisawa N, Arai T, et al
    Association Between Acute Kidney Injury and the Trendelenburg Position Angle During Robot-assisted Radical Prostatectomy.
    Anticancer Res. 2024;44:1767-1772.
    >> Share

  35. KASHIWAGI E, Kawahara T, Kinoshita F, Shiota M, et al
    The Role of Adipocytokines and their Receptors in Prostate Cancer: Adiponectin May Protect Against Progression.
    Anticancer Res. 2024;44:1369-1376.
    >> Share

  36. CHANG CC, Chiou JK, Lin CJ, Lu K, et al
    Machine-learning Algorithm-based Risk Prediction and Screening-detected Prostate Cancer in A Benign Prostate Hyperplasia Cohort.
    Anticancer Res. 2024;44:1683-1693.
    >> Share

    March 2024
  37. HOLM I, Hernroth B, Rosander A, Tassidis H, et al
    Manganese as a Possible Anticancer Enhancer in Docetaxel Treatment of Prostate Cancer Cells.
    Anticancer Res. 2024;44:953-962.
    >> Share

  38. YAMAMICHI G, Kato T, Watabe T, Hatano K, et al
    Current Status of Prostate-specific Membrane Antigen-targeted Alpha Radioligand Therapy in Prostate Cancer.
    Anticancer Res. 2024;44:879-888.
    >> Share

  39. HERNANDEZ-VALENCIA CG, Rodriguez-Martinez G, Carriles-Perez AM, Gonzalez-Perez D, et al
    Antiproliferative and Antimigratory Activity of Poly-gallic Acid in Cancer Cell Lines.
    Anticancer Res. 2024;44:1201-1208.
    >> Share

    February 2024
  40. DELL'ATTI L
    Biparametric MRI for Local Staging of Prostate Cancer: Current Status and Future Applications.
    Anticancer Res. 2024;44:463-470.
    >> Share

  41. KUROKAWA G, Mori K, Sasaki H, Nakano J, et al
    Effectiveness of Magnetic Resonance Imaging/Ultrasound-guided Target Biopsy in Detecting Clinically Significant Prostate Cancer.
    Anticancer Res. 2024;44:679-686.
    >> Share

  42. SAKAMOTO S, Ando K, Pae S, Zhao X, et al
    Copy Number Gain in Androgen Receptors Predicts the Poor Prognosis in Japanese Castration-resistant Prostate Cancer.
    Anticancer Res. 2024;44:639-647.
    >> Share

    January 2024
  43. OKA D, Sekine Y, Tsuji Y, Nakayama H, et al
    Simvastatin Enhances the Radiosensitivity of Androgen-independent Prostate Cancer Cells via Inhibition of RAD51 Expression.
    Anticancer Res. 2024;44:93-98.
    >> Share

  44. REINIKAINEN P, Lehtinen I, Luukkaala T, Kellokumpu-Lehtinen PL, et al
    Safer and More Convenient Modern Curative Radiotherapy for Patients With Early Prostate Cancer.
    Anticancer Res. 2024;44:139-150.
    >> Share

    December 2023
  45. MIYAZAWA Y, Sekine Y, Oka D, Nakazawa S, et al
    Simvastatin Induces Autophagy and Inhibits Proliferation in Prostate Cancer Cells.
    Anticancer Res. 2023;43:5377-5386.
    >> Share

  46. MAEDA-MINAMI A, Nishikawa T, Ishikawa H, Mutoh M, et al
    Angiotensin II Receptor Blockers Cause Changes in Prostate-specific Antigen Levels: A Retrospective Cohort Study.
    Anticancer Res. 2023;43:5629-5636.
    >> Share

  47. FUKUI Y, Yamada Y, Sakamoto S, Horikoshi T, et al
    Preoperative PI-RADS v2.1 Scoring System Improves Risk Classification in Patients Undergoing Radical Prostatectomy.
    Anticancer Res. 2023;43:5705-5712.
    >> Share

  48. SMULDERS-SRINIVASAN TK, Jenkinson SE, Brown LJ, Lenis VP, et al
    PDIA6 and Maspin in Prostate Cancer.
    Anticancer Res. 2023;43:5331-5340.
    >> Share

    November 2023
  49. YAMAMOTO T, Umezawa R, Shimada S, Takahashi N, et al
    The Impact of Pathological Grade Group 3 on Relapse-free Survival After Salvage Radiotherapy for Postoperative Prostate Cancer.
    Anticancer Res. 2023;43:5115-5125.
    >> Share

    October 2023
  50. KANO H, Izumi K, Nakagawa R, Toriumi R, et al
    Role of Positive Biopsy Core Ratio in Prostate Cancer Patients.
    Anticancer Res. 2023;43:4619-4626.
    >> Share

  51. NAGATA Y, Jojima K, Matsukawa T, Tomisaki I, et al
    Initial-to-nadir Prostate-specific Antigen Ratio Predicts Response to First-line Enzalutamide in Metastatic Castration-resistant Prostate Cancer.
    Anticancer Res. 2023;43:4573-4581.
    >> Share

  52. KUSUHARA Y, Fukawa T, Fukumori T, Ueno Y, et al
    Effect of Positive Biopsy Core Rate on Low-dose-rate Brachytherapy Outcomes in Intermediate-risk Prostate Cancer.
    Anticancer Res. 2023;43:4627-4635.
    >> Share

  53. URABE F, Kobayashi D, Iwatani K, Imai YU, et al
    The Efficacy and Safety of a Low Relative Dose Intensity of Cabazitaxel in Patients With Metastatic Castration-resistant Prostate Cancer.
    Anticancer Res. 2023;43:4611-4617.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016